Bristol-Myers Squibb (BMY) Tops Q3 EPS by 30c, provides guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $57.54 -0.74%
EPS Growth %: +10.3%
Financial Fact:
Net Earnings Attributable to Noncontrolling Interest: 13M
Today's EPS Names:
CRMT, PKE, HELE, More
EPS Growth %: +10.3%
Financial Fact:
Net Earnings Attributable to Noncontrolling Interest: 13M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.80, $0.30 better than the analyst estimate of $1.50. Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $11.26 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2024 EPS of $0.75-$0.95, versus the consensus of $0.71.
Revenues are expected to be ~5% increased over the prior guidance of Upper end of low single-digit range
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
- PriceSmart (PSMT) Misses Q3 EPS by 4c, Beats on Revenue
- Callan JMB and Alabama State University form campus partnership
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
